Teacher Retirement System of Texas Has $341,000 Position in Amneal Pharmaceuticals, Inc. $AMRX

Teacher Retirement System of Texas grew its holdings in Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) by 12.2% in the second quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 42,124 shares of the company’s stock after purchasing an additional 4,596 shares during the period. Teacher Retirement System of Texas’ holdings in Amneal Pharmaceuticals were worth $341,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also modified their holdings of AMRX. Vanguard Group Inc. raised its position in Amneal Pharmaceuticals by 6.2% during the first quarter. Vanguard Group Inc. now owns 15,762,727 shares of the company’s stock valued at $132,092,000 after buying an additional 920,758 shares during the period. Nantahala Capital Management LLC grew its stake in Amneal Pharmaceuticals by 3.9% during the 1st quarter. Nantahala Capital Management LLC now owns 3,808,561 shares of the company’s stock valued at $31,916,000 after acquiring an additional 143,032 shares in the last quarter. BlackBarn Capital Partners LP grew its stake in Amneal Pharmaceuticals by 1.1% during the 1st quarter. BlackBarn Capital Partners LP now owns 2,881,654 shares of the company’s stock valued at $24,148,000 after acquiring an additional 31,654 shares in the last quarter. Acadian Asset Management LLC increased its holdings in shares of Amneal Pharmaceuticals by 51.3% in the 1st quarter. Acadian Asset Management LLC now owns 2,598,294 shares of the company’s stock valued at $21,759,000 after purchasing an additional 880,471 shares during the period. Finally, Nuveen LLC purchased a new stake in shares of Amneal Pharmaceuticals in the first quarter worth approximately $19,581,000. Institutional investors and hedge funds own 31.82% of the company’s stock.

Insider Activity at Amneal Pharmaceuticals

In other Amneal Pharmaceuticals news, Director John Kiely sold 32,000 shares of the firm’s stock in a transaction on Wednesday, August 27th. The shares were sold at an average price of $9.23, for a total value of $295,360.00. Following the sale, the director directly owned 225,433 shares in the company, valued at $2,080,746.59. This trade represents a 12.43% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, EVP Andrew S. Boyer sold 279,244 shares of the company’s stock in a transaction dated Wednesday, August 20th. The shares were sold at an average price of $9.38, for a total transaction of $2,619,308.72. Following the transaction, the executive vice president directly owned 152,426 shares of the company’s stock, valued at $1,429,755.88. This represents a 64.69% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 503,770 shares of company stock worth $4,746,929 in the last 90 days. 26.56% of the stock is owned by company insiders.

Amneal Pharmaceuticals Stock Performance

Shares of AMRX stock opened at $11.48 on Tuesday. The stock’s 50 day simple moving average is $10.19 and its 200 day simple moving average is $8.83. Amneal Pharmaceuticals, Inc. has a twelve month low of $6.68 and a twelve month high of $11.88. The company has a market capitalization of $3.61 billion, a price-to-earnings ratio of 1,149.15 and a beta of 1.21.

Amneal Pharmaceuticals (NASDAQ:AMRX) last announced its earnings results on Thursday, October 30th. The company reported $0.17 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.12 by $0.05. Amneal Pharmaceuticals had a negative return on equity of 189.49% and a net margin of 0.12%.The firm had revenue of $784.51 million during the quarter. Amneal Pharmaceuticals has set its FY 2025 guidance at 0.750-0.80 EPS. On average, analysts forecast that Amneal Pharmaceuticals, Inc. will post 0.53 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

AMRX has been the topic of a number of research analyst reports. JPMorgan Chase & Co. boosted their price objective on shares of Amneal Pharmaceuticals from $12.00 to $14.00 and gave the company an “overweight” rating in a research report on Tuesday, September 16th. Piper Sandler reissued an “overweight” rating and set a $13.00 target price (up previously from $11.00) on shares of Amneal Pharmaceuticals in a research note on Friday, October 31st. Finally, Weiss Ratings reaffirmed a “hold (c)” rating on shares of Amneal Pharmaceuticals in a research note on Wednesday, October 8th. Four investment analysts have rated the stock with a Buy rating and one has given a Hold rating to the stock. According to data from MarketBeat.com, Amneal Pharmaceuticals presently has a consensus rating of “Moderate Buy” and a consensus price target of $12.50.

Amneal Pharmaceuticals Profile

Amneal Pharmaceuticals, Inc, together with its subsidiaries, develops, manufactures, markets, and distributes generics, injectables, biosimilars, and specialty branded pharmaceutical products worldwide. The company operates through three segments: Generics, Specialty, and AvKARE. The Generics segment offers immediate and extended release oral solid, powder, liquid, sterile injectable, nasal spray, inhalation and respiratory, biosimilar, ophthalmic, film, transdermal patch, and topical products.